Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial
Authors:
- Isobel G. LavenderILIsobel G. Lavender
- Nathaniel S. MarshallNMNathaniel S. Marshall
- Danielle McCartneyDMDanielle McCartney
- Garry ChoGCGarry Cho
- Anastasia SuraevASAnastasia Suraev
- Jonathon C. ArnoldJAJonathon C. Arnold
- Angela L. D'ROzarioADAngela L. D'ROzario
- Christopher J. GordonCGChristopher J. Gordon
- Bandana SainiBSBandana Saini
- Sheila SivamSSSheila Sivam
- 16 February 2026
- journal article
- Published by Wiley in Journal of Sleep Research
- Vol. 35 (4) , e70284
Abstract
Insomnia disorder is harmful and requires novel treatments. Cannabinol, an oxidative by‐product of Δ9‐tetrahydrocannabinol, is claimed to be a hypnotic, but its effects on objective sleep and insomnia remain unknown. This randomized, double‐blind, placebo‐controlled, three‐arm, single‐night crossover trial evaluated the acute efficacy and safety of cannabinol for insomnia disorder. Twenty adults (aged 25–65) with physician‐diagnosed insomnia disorder (meeting DSM‐5 and ICSD‐3 criteria; Insomnia Severity Index ≥ 15) were enrolled at the Woolcock Institute of Medical Research (Sydney, Australia) between August 2022 and September 2023. Participants received a single 2 mL oral dose of 30 mg (1.5%) or 300 mg (15%) cannabinol, or matched placebo (2‐week washout). All participants (17 female and 3 males; mean ± SD age 42 ± 13 years) completed the protocol and were statistically analysed. The primary outcome was wake after sleep onset (WASO) minutes, measured by overnight polysomnography. Cannabinol did not significantly change WASO (300 mg: −6.3 min [95% CI: −18.2, +5.5], p = 0.29, dz = −0.22; 30 mg: −4.0 min [−15.9, +7.9], p = 0.50, dz = 0.11). However, 300 mg cannabinol increased non‐rapid eye movement‐2 sleep ( p = 0.03, dz = 0.54), subjective sleep quality ( p = 0.005, dz = 0.56); and reduced sleep onset latency ( p = 0.004, dz = −0.74) and electroencephalographic arousal indices ( p = 0.02, dz = −0.65). There were 247 mild‐to‐moderate adverse events across arms. Larger, longer trials are warranted. ClinicalTrials.gov Identifier: NCT05344170.Keywords
Funding Information
- National Health and Medical Research Council (1197439)
This publication has 73 references indexed in Scilit:
- How long does a single oral dose of cannabidiol persist in plasma? Findings from three clinical trialsDrug Testing and Analysis, 2022
- A validated method for the simultaneous quantification of cannabidiol, Δ9‐tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open‐label trialDrug Testing and Analysis, 2020
- The effect of cannabidiol on simulated car driving performance: A randomised, double‐blind, placebo‐controlled, crossover, dose‐ranging clinical trial protocolHuman Psychopharmacology: Clinical and Experimental, 2020
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia DisorderJAMA Network Open, 2019
- Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use CannabisJAMA Network Open, 2018
- Guidelines for the Content of Statistical Analysis Plans in Clinical TrialsJAMA, 2017
- Rewarding, Stimulant, and Sedative Alcohol Responses and Relationship to Future Binge DrinkingArchives of General Psychiatry, 2011
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007
- Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ 9-Tetrahydrocannibinol, Cannabidiol and Cannabinol2005
- Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smokingJournal of Mass Spectrometry, 1987